Title: Phase II study of E7070 in patients with metastatic melanoma
Authors: Smyth, JF ×
Aamdal, S
Awada, A
Dittrich, C
Caponigro, F
Schöffski, Patrick
Gore, M
Lesimple, T
Djurasinovic, N
Baron, B
Ravic, M
Fumoleau, P
Punt, CJA #
Issue Date: Jan-2005
Publisher: Kluwer Academic Publishers
Series Title: Annals of Oncology vol:16 issue:1 pages:158-161
Abstract: E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science